Initially theorized in 2004 by Dr. Ethan Russo, Clinical Endo-Cannabinoid Deficiency is thought to be responsible for migraines, fibromyalgia, inflammatory bowel disease and other related conditions that affect nearly 20 percent of Americans daily. In January of this year, a unique partnership between Anantlife’s Dr. Rahul Kushwah and Cannalogix Foundation’s Chief Research Officer, J.B. Creel commenced for the benefit of all patients seeking relief from the systemic effects of an imbalanced Endo-Cannabinoid System.
By February, the collaboration had already shown results with the development of the world’s first genetic kit measuring a Clinical Endo-Cannabinoid Deficiency. We sat down to discuss the partnership with Dr. Rahul Kushwah and Mr. J.B. Creel, a passionate duo whose keen sense of caring and impeccable global awareness are paving the way forward for patient-centered medical, cannabis research.
Thank you, both for taking the time out to speak with us today. Before we begin, can